Across TCGA pan-cancer cohorts, C17orf97 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C17orf97 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher C17orf97 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated C17orf97 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where C17orf97 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.738	0.234	.003	27	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	16	view →
GBM	DFS	Tertile	All	0.859	0.651	.029	3	view →
HNSC	OS	Median	III,IV	0.764	0.917	.049	1	view →
CCRCC	DFS	Quartile	All	0.957	0.524	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: C17orf97 tumor-vs-normal RNA expression · all C17orf97 data types